Synergy CHC Corp. Reports Fourth Quarter and Full Year 2025 Financial Results

NORTH WINDHAM, Maine, April 01, 2026 (GLOBE NEWSWIRE) — Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health and wellness company, is announcing its financial results for the three and twelve months ended December 31, 2025.

“Our full year results reflect a year of meaningful strategic progress and continued advancement of our priority growth initiatives,” said Jack Ross, CEO of Synergy CHC Corp. “During 2026 on the beverage side, we have shipped our Focus and Energy RTDs and shots into several new key distribution partners, including EG America, Wakefern Food, and Pine State Beverage, to name a few. With millions of cans of RTDs and shots in stock and ready to ship, we believe 2026 will be a foundational year for scaling the beverage division and expanding our national footprint. In fact, through the first quarter of 2026, we’ve already generated over $600,000 in gross revenue, nearly matching our full year 2025 performance. This equates to an annualized run rate of approximately $2.5 million, reflecting the meaningful progress we’ve made in expanding our functional beverage distribution.”

“In addition, due to instability in the Middle East, we agreed to cancel a licensing agreement with our regional partner. However, we continue to view this as an attractive long-term growth opportunity and intend to revisit this once conditions in the region stabilize. With a more focused portfolio, expanding retail and DSD partnerships, and growing consumer momentum, we believe Synergy is well positioned to drive sustainable growth in the quarters ahead.”

Fourth Quarter 2025 Financial Summary vs. Same Year-Ago Period

  • Revenue of $6.07 million vs. $10.27 million.
  • Gross margin of 36.6% vs. 63.3%.
  • Income (loss) from operations of ($13.31) million vs. $1.35 million.
  • Net income (loss) of ($14.82) million vs. $105.7 thousand.
  • Earnings (loss) per share of ($1.35) vs. $0.01.
  • EBITDA (loss), a non-GAAP financial measure, was ($13.28) million vs. $1.68 million.
  • Adjusted EBITDA (loss), a non-GAAP financial measure, was $(4.48) million vs. $2.79 million.

2025 Financial Summary vs. Same Year-Ago Period

  • Revenue of $30.38 million vs. $34.83 million.
  • Gross margin of 66.8% vs. 67.9%.
  • Income (loss) from operations of ($8.46) million vs. $5.80 million.
  • Net income (loss) of ($12.34) million vs. $2.12 million.
  • Earnings (loss) per share of ($1.27) vs. $0.28.
  • EBITDA (loss), a non-GAAP financial measure, was ($6.19) million vs. $6.46 million.
  • Adjusted EBITDA, a non-GAAP financial measure, was $800 thousand vs. $7.35 million.

Fourth Quarter and Full Year 2025 Financial Results

Revenue in the fourth quarter of 2025 was $6.07 million compared to $10.27 million in the fourth quarter of 2024, due to the termination of the license of $2.9 million. For the full year 2025, revenue was $30.38 million compared to $34.83 million in 2024, due to the termination of license agreement of $2.9 million.

Gross margin in the fourth quarter of 2025 was 36.6% compared to 63.3% in the fourth quarter of 2024 due to the termination of license agreement of $2.9 million and a write off of obsolete inventory of $1.04 million. Without those two items, gross margin would have been 68.8%. For the full year 2025, gross margin was 66.8% compared to 67.9% in 2024.

Operating expenses in the fourth quarter of 2025 were $15.53 million compared to $5.14 million in the fourth quarter of 2024. This is largely due to one-time items of an allowance for bad debt of $6.66 million and the write off of prepaid media credits of $0.9 million. Without those two items, operating expenses would have been $8.00 million. For the full year 2025, operating expenses were $28.76 million compared to $17.84 million in 2024, which is also due to the above-mentioned one-time items. Without those two items, operating expenses would have been $21.24 million.

Income (loss) from operations for the fourth quarter of 2025 was ($13.31) million compared to $1.35 million in the fourth quarter of 2024. This is largely due to one-time items of allowance for bad debt of $6.66 million, termination of license agreement of $2.9 million, write off of obsolete inventory of $1.04 million and write off of prepaid media credits of $0.9 million. Without those one-time items, loss from operations would have been $(1.85) million. For the full year 2025, income (loss) from operations was ($8.46) million compared to $5.80 million in 2024, which is also due to the items listed above. Without those one-time items, the full year income from operations would have been $3.0 million.

Net income (loss) in the fourth quarter of 2025 was ($14.82) million compared to net income of $105.7 thousand in the fourth quarter of 2024. This is largely due to one-time items of allowance for bad debt of $6.66 million, termination of license agreement of $2.9 million, write off of obsolete inventory of $1.04 million and write off of prepaid media credits of $0.9 million. Without those one-time items, net loss would have been $(3.35) million. For the full year 2025, net income (loss) was ($12.34) million compared to $2.12 million in 2024, which is also due to the items listed above offset by a gain on the settlement of notes payable of $2.15 million. Without those one-time items, the full year net loss would have been $(3.03) million.

Earnings (loss) per share in the fourth quarter of 2025 was ($1.35) compared to $0.01 in the fourth quarter of 2024. For the full year 2025, earnings (loss) per share was ($1.27) compared to $0.28 in 2024.

EBITDA (loss) (a non-GAAP financial measure) in the fourth quarter of 2025 was ($13.28) million compared to $1.68 million in the fourth quarter of 2024. For the full year 2025, EBITDA (loss) was ($6.19) million compared to $6.46 million in 2024.

Adjusted EBITDA (loss) (a non-GAAP financial measure) in the fourth quarter of 2025 was $(4.48) million compared to $2.79 million in the fourth quarter of 2024. For the full year 2025, Adjusted EBITDA was $800 thousand compared to $7.35 million in 2024.

Balance Sheet and Cash Flow

As of December 31, 2025, Synergy had approximately $2.6 million in cash and cash equivalents, compared to $687.9 thousand in cash and cash equivalents as of December 31, 2024.

As of December 31, 2025, Synergy had a working capital surplus of $1.78 million, compared to a $1.12 million working capital deficit as of December 31, 2024.

As of December 31, 2025, Synergy had $3.7 million in inventory, compared to $1.7 million in inventory as of December 31, 2024.

Cash used in operating activities for the twelve months ended December 31, 2025 was $2.6 million compared to cash used in operating activities of $4.8 million for the twelve months ended December 31, 2024.

Non-GAAP Financial Measure Reconciliation: EBITDA and Adjusted EBITDA

To assist financial statement users in an assessment of our historical performance, the Company discloses non-GAAP financial measures in press releases and on investor conference calls and related events, as the Company believes that the non-GAAP information enhances investors’ overall understanding of our financial performance, and should be read in addition to, rather than instead of, the financial statements prepared in accordance with GAAP.

Management believes EBITDA and Adjusted EBITDA provide useful information to investors by excluding certain items that may not be indicative of the Company’s core operating results and that can vary significantly between periods. EBITDA is defined as net income plus interest expense, income tax expense, depreciation and amortization. Adjusted EBITDA is calculated as EBITDA plus or minus foreign exchange gains or losses, one-time expenses and non-cash expenses. Since Adjusted EBITDA is a non-GAAP financial performance measure, the Company’s calculation of Adjusted EBITDA may not be comparable to other similarly titled measures of other companies; and should not be considered in isolation, as a substitute for, or superior to measures of financial performance prepared in accordance with GAAP.

The following table reconciles net income to EBITDA and Adjusted EBITDA (in millions of US dollars):

   
  3 Months ended December 31
  2025 2024
     
Net income for the period $
(14.81
)
$
0.10
Adjusted for:    
Interest expense, net 1.55 1.54
Amortization of intangible assets 0.03 0.03
Tax expense (benefit) (0.05) 0.01
EBITDA $
(13.28
)
$
1.68
One-time expenses 0.86 0.99
Allowance for bad debts 6.66 0.00
Obsolete inventory 1.04 0.13
Foreign currency adjustment (0.13) 0.00
Stock based compensation 0.37
Adjusted EBITDA $
(4.48
)
$
2.79

   
  12 Months ended December 31
  2025 2024
     
Net income (loss) for the period $
(12.34
)
$
2.12
Adjusted for:    
Interest expense, net 5.90 4.11
Amortization of intangible assets 0.13 0.13
Tax expense 0.12 0.10
EBITDA $
(6.19
)
$
6.46
One-time expenses 0.86 0.74
Allowance for bad debts 6.66 0.00
Gain on settlement of loan (2.15) 0.00
Obsolete inventory 1.04 0.13
Foreign currency adjustment 0.02 0.03
Stock based and board compensation 0.56 0.00
Adjusted EBITDA $
0.80
$
7.35
     

Conference Call

In conjunction with this announcement, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT on April 1, 2026, with the Company’s Chief Executive Officer, Jack Ross, and the Company’s Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy’s website. To access the call by phone, please register here and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time on the Company’s website.

About Synergy CHC Corp.

Synergy CHC Corp. develops and markets consumer health and wellness products, led by its flagship brands FOCUSfactor® and Flat Tummy®. FOCUSfactor®, a clinically studied brain health supplement and functional beverage line with a 25-year legacy, enjoys established distribution in the U.S., Canada and Mexico. through major retailers including Costco, Walmart, Amazon, BJ’s, and Walgreens, among others. Flat Tummy® complements Synergy’s portfolio as a lifestyle brand focused on women’s wellness and weight management.

Forward Looking Statements

Certain statements contained in this press release constitute “forward-looking statements,” including statements regarding brand expansion and growth initiatives. These forward-looking statements represent Synergy’s expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, which are set forth in Synergy’s registration statement on Form S-1, as amended, many of which are outside of Synergy’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements.

Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Synergy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in Synergy’s filings with the SEC. The risk factors and other factors noted in Synergy’s filings could cause its actual results to differ materially from those contained in any forward-looking statement.

Investor Relations

Gateway Group
Cody Slach, Greg Robles
949.574.3860
[email protected] 

Synergy CHC Corp.

Condensed Consolidated Balance Sheets
             
    December 31,
2025
    December 31,
2024
 
Assets            
Current Assets            
Cash and cash equivalents   $ 2,622,313     $ 687,920  
Restricted cash     100,000       100,000  
Accounts receivable, net     3,203,505       5,321,037  
Other receivables, net           1,999,637  
Loan receivable (related party), net           4,375,059  
Prepaid expenses (including related party amount of $110,803 and $312,966, respectively)     351,049       1,859,563  
Inventory, net     3,737,509       1,716,552  
Total Current Assets     10,014,376       16,059,768  
                 
Intangible assets, net     150,000       283,333  
                 
Total Assets   $ 10,164,376     $ 16,343,101  
                 
Liabilities and Stockholders’ Deficit                
Current Liabilities:                
Accounts payable and accrued liabilities (including payable to shareholder of $196,934 and $88,644, respectively)   $ 6,388,219     $ 5,191,868  
Income taxes payable     88,108       242,977  
Contract liabilities     1,526       24,252  
Short term loans payable, net of debt discount, related party     100,000        
Short term loans payable, net of debt discount           7,725,272  
Current portion of notes payable, net of debt discount     1,658,215        
Current portion of long-term notes payable, net of debt discount and debt issuance cost, shareholder           4,000,000  
Total Current Liabilities     8,236,068       17,184,369  
                 
Long-term Liabilities:                
Notes payable, net of debt discount, shareholder           8,333,053  
Notes payable, net of debt discount     25,056,446       7,457,022  
Total long-term liabilities     25,056,446       15,790,075  
Total Liabilities     33,292,514       32,974,444  
                 
Commitments and contingencies (Note 13)                
                 
Stockholders’ Deficit:                
Common stock, $0.00001 par value; 300,000,000 shares authorized; 11,483,926 and 8,721,818, shares issued, respectively; 11,303,853 and 8,541,745 outstanding, respectively     114       87  
Additional paid in capital     33,594,550       27,643,660  
Accumulated other comprehensive loss     (154,281 )     (47,777 )
Accumulated deficit     (56,441,021 )     (44,099,813 )
Less: Treasury stock (180,073 shares) at cost     (127,500 )     (127,500 )
Total stockholders’ deficit     (23,128,138 )     (16,631,343 )
Total Liabilities and Stockholders’ Deficit   $ 10,164,376     $ 16,343,101  
                 

Synergy CHC Corp.

Consolidated Statements of Operations and Other Comprehensive (Loss) Income
             
    For the

year ended
    For the

year ended
 
    December 31,

2025
    December 31,

2024
 
Revenue   $ 30,380,809     $ 34,834,243  
                 
Cost of sales     10,077,992       11,191,224  
                 
Gross Profit     20,302,817       23,643,019  
                 
Operating expenses                
Selling and marketing     13,137,779       12,991,431  
General and administrative     8,829,803       4,717,006  
Reserve for bad debts     6,660,650        
Depreciation and amortization     133,334       133,334  
Total operating expenses     28,761,566       17,841,771  
                 
(Loss) Income from operations     (8,458,749 )     5,801,248  
                 
Other (income) expenses                
Other income           (510,534 )
Interest income     (15,065 )     (1,523 )
Interest expense     5,919,742       4,105,198  
Gain on settlement of notes payable     (2,154,522 )      
Remeasurement loss (gain) on translation of foreign subsidiary     14,833       (18,954 )
                 
Total other expenses     3,764,988       3,574,187  
                 
Net (loss) income before income taxes     (12,223,737 )     2,227,061  
Income tax expense     117,471       102,085  
                 
Net (loss) income after tax   $ (12,341,208 )   $ 2,124,976  
                 
Net (loss) income per share – basic   $ (1.27 )   $ 0.28  
Net (loss) income per share – diluted   $ (1.27 )   $ 0.28  
                 
Weighted average common shares outstanding                
Basic     9,722,552       7,588,095  
Diluted     9,722,552       7,630,501  
Comprehensive (loss) income:                
Net (loss) income   $ (12,341,208 )   $ 2,124,976  
Foreign currency translation adjustment     (106,504 )     54,690  
Comprehensive (loss) income   $ (12,447,712 )   $ 2,179,666  
                 

Synergy CHC Corp.

Consolidated Statements of Cash Flows
             
    For the

year ended
    For the

year ended
 
    December 31,
2025
    December 31,
2024
 
Cash Flows from Operating Activities            
Net (loss) income   $ (12,341,208 )   $ 2,124,976  
Adjustments to reconcile net (loss) income to net cash used in operating activities:                
Amortization of debt discount and debt issuance cost     1,633,776       56,796  
Depreciation and amortization     133,334       133,334  
Stock based compensation     136,247        
Stock issued for modification of notes payable     847,062        
Stock issued for services     127,200        
Foreign currency transaction (gain) loss     5,531       54,321  
Remeasurement gain on translation of foreign subsidiary     14,833       (18,954 )
Non cash implied interest           4,799  
Bad debts     2,256,846        
Bad debt, related party     4,403,804        
Gain on settlement of debt     (2,154,522 )      
Write-off of inventory     894,341       125,364  
Stock issued for loan financing           97,920  
Income from employee retention credits           (252,405 )
Income from insurance on stolen goods           (258,129 )
Changes in operating assets and liabilities:                
Accounts receivable     1,514,935       (3,214,943 )
Other receivables     345,388       (1,489,103 )
Loan receivable, related party           84,937  
Inventory     (2,915,298 )     1,884,324  
Prepaid expenses     1,306,351       (1,250,023 )
Prepaid expense, related party     202,163       (145,092 )
Income taxes payable     (84,271 )     57,312  
Contract liabilities     (22,726 )     10,050  
Accounts payable and accrued liabilities     622,099       (2,870,633 )
Accounts payable, related party     489,093       61,759  
Net cash used in operating activities     (2,585,022 )     (4,803,390 )
                 
Cash Flows from Investing Activities            
                 
Cash Flows from Financing Activities                
Proceeds from issuance of common stock at IPO           8,397,044  
Proceeds from issuing common stock     3,719,547        
Advances from related party     235,000       3,528,003  
Repayments of advances to related party     (135,000 )     (3,200,000 )
Repayment of notes payable, shareholder     (10,000,000 )     (84,500 )
Proceeds from notes payable     20,996,250       1,360,000  
Payment of loan financing fees     (2,024,287 )      
Repayment of notes payable     (8,136,846 )     (5,196,461 )
Net cash provided by financing activities     4,654,664       4,804,086  
                 
Effect of exchange rate on cash, cash equivalents and restricted cash     (135,249 )     54,690  
Net increase in cash, cash equivalents and restricted cash     1,934,393       55,386  
Cash, Cash Equivalents and restricted cash, beginning of year     787,920       732,534  
Cash, Cash Equivalents and restricted cash, end of year   $ 2,722,313     $ 787,920  
                 
Supplemental Disclosure of Cash Flow Information:                
Cash paid during the period for:                
Interest   $ 2,953,878     $ 3,906,001  
Income taxes   $ 147,377     $  
                 
Supplemental Disclosure of Non-cash Investing and Financing Activities:                
Accounts payable converted to loan payable upon settlement   $     $ 3,770,824  
Reduction of short-term related party note payable by reduction of prepaid balance   $     $ 328,003  
Issuance of common stock for loan financing   $ 220,869     $  
Issuance of pre-funded warrants for settlement of shareholder notes payable   $ 899,993     $  
Exercise of pre-funded warrants   $ 4     $  
Loan fees payable to lender   $ 375,000     $